Wednesday, July 30, 2014 5:11:32 PM
1/14 there is a picture of him holding a vial of the TLR-4 agonist and you have to scroll down to 1/12 to see a detailed description of EP IL-12.
For such a rare disease it's tough to be involved with what appears to be 3 separate projects (clinicaltrials.gov only lists two MCC trials, but this site list three separate agents). There just aren't enough patients.
The bottom line is that this Dr. Bhatia is an internationally recognized MCC expert and Oncosec needs to do their part to keep him engaged and enrolling patients.
The answer to your second question is yes, Toll like receptor agonist 4 agents do function as immunomodulators. They are among a newer class of agents
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM